Passage Bio/$PASG
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Passage Bio
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
- Ticker
- $PASG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 24
- Headquarters
- Philadelphia, United States
- Website
- www.passagebio.com
Passage Bio Metrics
BasicAdvanced
$13M
-
-$10.33
-
-
Price and volume
Market cap
$13M
52-week high
$20.00
52-week low
$3.29
Average daily volume
17K
Financial strength
Current ratio
1.002
Quick ratio
0.972
Profitability
EBITDA (TTM)
-34.046
Management effectiveness
Return on assets (TTM)
-45.26%
Return on equity (TTM)
-212.27%
Valuation
Price to book
257.43
Price to tangible book (TTM)
257.43
Price to free cash flow (TTM)
-0.392
Free cash flow yield (TTM)
-254.80%
Free cash flow per share (TTM)
-10.192
Growth
Earnings per share change (TTM)
-27.74%
3-year earnings per share growth (CAGR)
-36.90%
What the Analysts think about Passage Bio
Analyst ratings (Buy, Hold, Sell) for Passage Bio stock.
Analyst projections of the future price of Passage Bio stock.
Passage Bio Financial Performance
Revenues and expenses
Passage Bio Earnings Performance
Company profitability
Upcoming events
No upcoming events
Passage Bio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.